

Vanita R Aroda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6083482/publications.pdf>

Version: 2024-02-01

82
papers

5,547
citations

147801

31
h-index

85541

71
g-index

84
all docs

84
docs citations

84
times ranked

4947
citing authors

#	ARTICLE	IF	CITATIONS
1	9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Medical Care in Diabetesâ€™2022</i>. Diabetes Care, 2022, 45, S125-S143.	8.6	534
2	Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes and Endocrinology, 2018, 6, 275-286.	11.4	443
3	Vitamin D Supplementation and Prevention of Type 2 Diabetes. New England Journal of Medicine, 2019, 381, 520-530.	27.0	423
4	6. Glycemic Targets: <i>Standards of Medical Care in Diabetesâ€™2022</i>. Diabetes Care, 2022, 45, S83-S96.	8.6	388
5	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care, 2018, 41, 258-266.	8.6	350
6	Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1754-1761.	3.6	336
7	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes and Endocrinology, 2017, 5, 355-366.	11.4	288
8	Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clinical Therapeutics, 2012, 34, 1247-1258.e22.	2.5	229
9	PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, 1724-1732.	8.6	227
10	A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. GeroScience, 2018, 40, 419-436.	4.6	221
11	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care, 2016, 39, 1972-1980.	8.6	198
12	A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 22-33.	4.4	183
13	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care, 2019, 42, 2262-2271.	8.6	146
14	Scientific Statement: Socioecological Determinants of Prediabetes and Type 2 Diabetes. Diabetes Care, 2013, 36, 2430-2439.	8.6	130
15	The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes/Metabolism Research and Reviews, 2011, 27, 528-542.	4.0	86
16	Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care, 2019, 42, 601-608.	8.6	82
17	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. Diabetes Care, 2016, 39, 1579-1586.	8.6	72
18	Metabolic and Hormonal Changes Induced by Pioglitazone in Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 469-476.	3.6	62

#	ARTICLE	IF	CITATIONS
19	Development of clinical trials to extend healthy lifespan. <i>Cardiovascular Endocrinology and Metabolism</i> , 2018, 7, 80-83.	1.1	59
20	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>JAMA Cardiology</i> , 2020, 5, 1182.	6.1	59
21	Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. <i>Fertility and Sterility</i> , 2008, 89, 1200-1208.	1.0	55
22	Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2203-2210.	4.4	55
23	Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: incidence and consequences. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 672-681.	4.4	53
24	Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1529-1536.	4.4	52
25	Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. <i>Diabetes Care</i> , 2019, 42, 2108-2116.	8.6	50
26	Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 596-605.	11.4	46
27	Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2019, 42, 2098-2107.	8.6	37
28	Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: Effects of pioglitazone and metformin treatment. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1587-1596.	3.4	36
29	Skin Intrinsic Fluorescence Correlates With Autonomic and Distal Symmetrical Polyneuropathy in Individuals With Type 1 Diabetes. <i>Diabetes Care</i> , 2011, 34, 1000-1005.	8.6	35
30	Skin Intrinsic Fluorescence Is Associated With Coronary Artery Disease in Individuals With Long Duration of Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2331-2336.	8.6	34
31	Apolipoprotein A1 is a hepatokine regulating muscle glucose metabolism and insulin sensitivity. <i>Nature Communications</i> , 2020, 11, 2024.	12.8	34
32	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. <i>Circulation</i> , 2021, 144, 74-84.	1.6	34
33	Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. <i>JAMA Network Open</i> , 2022, 5, e2148030.	5.9	30
34	Metformin and Type 2 Diabetes Prevention. <i>Diabetes Spectrum</i> , 2018, 31, 336-342.	1.0	26
35	Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes. <i>Postgraduate Medicine</i> , 2011, 123, 228-238.	2.0	25
36	Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2177-2182.	4.4	25

#	ARTICLE	IF	CITATIONS
37	Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c , BMI and diabetes duration categories in the LixiLan trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1408-1415.	4.4	23
38	Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e130-e138.	3.6	22
39	Cross-Sectional Evaluation of Noninvasively Detected Skin Intrinsic Fluorescence and Mean Hemoglobin A1c in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 117-123.	4.4	21
40	Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. <i>Current Diabetes Reports</i> , 2016, 16, 44.	4.2	19
41	Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 303-314.	4.4	19
42	Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. <i>Diabetes Care</i> , 2018, 41, 1590-1599.	8.6	16
43	Re-examining the widespread policy of stopping sodium-glucose cotransporter 2 inhibitors during acute illness: A perspective based on the updated evidence. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2071-2080.	4.4	16
44	Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials. <i>Diabetologia</i> , 2020, 63, 1516-1520.	6.3	15
45	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 41.	4.2	15
46	More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan and LixiLan . <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2314-2318.	4.4	14
47	Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. <i>Diabetes Care</i> , 2020, 43, 940-947.	8.6	14
48	Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO , a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2572-2581.	4.4	14
49	A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 979-994.	5.7	13
50	Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. <i>Postgraduate Medicine</i> , 2020, 132, 26-36.	2.0	12
51	Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonist in people with type 2 diabetes mellitus: A network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 136-146.	4.4	12
52	Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1338-1350.	4.4	12
53	iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1683-1689.	4.4	11
54	Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2170-2178.	4.4	11

#	ARTICLE	IF	CITATIONS
55	Islet Autoimmunity Is Highly Prevalent and Associated With Diminished β -Cell Function in Patients With Type 2 Diabetes in the GRADE Study. <i>Diabetes</i> , 2022, 71, 1261-1271.	0.6	11
56	Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?. <i>Clinical Diabetes</i> , 2018, 36, 138-147.	2.2	10
57	Impact of disease duration and β -cell reserve on the efficacy of switching to <i>iGlarLixi</i> in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the <i>LixiLan-G</i> trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1567-1576.	4.4	9
58	Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes. <i>Diabetes Care</i> , 2022, 45, 766-768.	8.6	8
59	Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. <i>Current Diabetes Reports</i> , 2019, 19, 157.	4.2	7
60	Glycaemic control and hypoglycaemia risk with insulin glargine 300%U/mL and insulin degludec 100%U/mL in older participants in the BRIGHT trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1588-1593.	4.4	7
61	Bedtime-to-Morning Glucose Difference and <i>iGlarLixi</i> in Type 2 Diabetes: Post Hoc Analysis of <i>LixiLan-L</i> . <i>Diabetes Therapy</i> , 2018, 9, 2155-2162.	2.5	6
62	A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100%units/mL at 26%weeks: DUAL VIII, a randomized trial designed to resemble clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 873-878.	4.4	6
63	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 <i>post hoc</i> analyses. <i>BMJ Open</i> , 2020, 10, e037883.	1.9	6
64	Reproducibility of a prediabetes classification in a contemporary population. <i>Metabolism Open</i> , 2020, 6, 100031.	2.9	6
65	Durable Effects of <i>iGlarLixi</i> Up to 52 Weeks in Type 2 Diabetes: The <i>LixiLan-G</i> Extension Study. <i>Diabetes Care</i> , 2021, 44, 774-780.	8.6	6
66	Diabetes With Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1599-1602.	2.8	6
67	REWIND to fast forward: time to revisit stroke prevention in type 2 diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 90-92.	11.4	5
68	Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001841.	2.8	5
69	Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of <i>LixiLan-L</i> . <i>Diabetes Therapy</i> , 2020, 11, 1007-1015.	2.5	5
70	Efficacy of <i>iGlarLixi</i> , a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2680-2684.	4.4	4
71	Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2021, 44, 2286-2292.	8.6	4
72	Differences in complications, cardiovascular risk factor, and diabetes management among participants enrolled at veterans affairs (VA) and non-VA medical centers in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE). <i>Diabetes Research and Clinical Practice</i> , 2022, 184, 109188.	2.8	4

#	ARTICLE	IF	CITATIONS
73	U.S. Preventive Services Task Force Criteria for Diabetes Screening. American Journal of Preventive Medicine, 2013, 45, 246-247.	3.0	2
74	Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. Current Cardiology Reports, 2017, 19, 25.	2.9	2
75	Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. Advances in Therapy, 2019, 36, 2310-2326.	2.9	2
76	Switching to <sc>iGlarLixi</sc> versus continuation of a daily or weekly glucagonâ€like peptideâ€ receptor agonist (<sc>GLP</sc>â€ <sc>RA</sc>) in insufficiently controlled type 2 diabetes: A <sc>LixiLanâ€G</sc> trial subgroup analysis by HbA1c and <sc>GLP</sc>â€ <sc>RA</sc> use at screening. Diabetes, Obesity and Metabolism, 2021, 23, 1331-1341.	4.4	2
77	EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction. Lancet Diabetes and Endocrinology,the, 2020, 8, 932-933.	11.4	1
78	Impact of Type 2 Diabetes (T2D) Duration on Response to iGlarLixi vs. iGlarâ€A Subanalysis of LixiLan-L. Diabetes, 2018, 67, 1094-P.	0.6	1
79	Guiding diabetes screening and prevention: rationale, recommendations and remaining challenges. Expert Review of Endocrinology and Metabolism, 2015, 10, 381-398.	2.4	0
80	Response to Letter to the Editor: â€œAndrogens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Programâ€ Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2068-2068.	3.6	0
81	SURPASSing the current dogma: is our framework shifting?. Lancet Diabetes and Endocrinology,the, 2022, , .	11.4	0
82	Clinical and Metabolic Characterization of Adults With Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Cohort. Diabetes Care, 2022, 45, 1512-1521.	8.6	0